Furthermore, due to the high proportion of hexokinase 2 (HK2)-positive PCs in tumors, reducing HK2/ROCK2 through shRNA or inhibitors can reduce the contractility of tumor PCs to rebuild the vascular system and thus improve drug delivery. The gene discussed is HK2; the disease is neoplasm.